AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance
April 25 2017 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the
appointment of Arpad Simon, M.D., to the role of vice president of
pharmacovigilance. Dr. Simon has worked in the pharmaceutical
industry for more than 20 years with extensive operational and
leadership experience in clinical development and
pharmacovigilance. Prior to joining AMAG, he served in
executive-level pharmacovigilance roles at Relypsa, Mitsubishi
Tanabe Pharma, Pfizer and other companies.
“Arpad’s vast experience in pharmacovigilance and risk
management will be invaluable to AMAG as the company continues to
expand. He understands how to build and successfully lead strong
pharmacovigilance programs in growth-oriented environments. We are
excited to have him join the team,” said Robert Kaper, M.D., senior
vice president, medical and scientific affairs at AMAG.
Dr. Simon will have responsibility for all pharmacovigilance
functions at AMAG, including product safety surveillance, aggregate
safety reporting and risk management. He will also oversee safety
evaluation across the company’s clinical development activities and
marketed therapeutics.
In addition to his leading roles in the pharmaceutical industry
both from a U.S. and global perspective, Dr. Simon also worked for
five years at the FDA Center for Drug Evaluation and Research. He
has successfully led and managed initiatives in the areas of
clinical trials, post-marketing safety, benefit-risk management,
business development, integration, process design and regulatory
interactions. Dr. Simon received his medical degree from Albert
Szent-Gyorgyi Medical University in Hungary.
Inducement Equity AwardsIn
connection with Dr. Simon’s entering into employment with AMAG, the
Board of Directors of AMAG approved awards to Dr. Simon of (i) an
option to purchase 13,100 shares of common stock and (ii) 1,800
restricted stock units. The option will have an exercise price
equal to the closing price of AMAG's common stock on the grant date
and will be exercisable in four equal annual installments beginning
on the first anniversary of the grant date. The option will have a
ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be
granted. The restricted stock units will vest in three equal annual
installments beginning on the first anniversary of the grant date
and will be subject to the restricted stock unit agreement pursuant
to which the restricted stock units will be granted. These equity
awards will be granted without stockholder approval as inducements
material to Dr. Simon entering into employment with AMAG in
accordance with NASDAQ Listing Rule 5635(c)(4).
About AMAG
AMAG is a biopharmaceutical company focused on developing and
delivering important therapeutics, conducting clinical research in
areas of unmet need and creating education and support programs for
the patients and families we serve. Our currently marketed products
support the health of patients in the areas of women’s and maternal
health, anemia management and cancer supportive care. Through CBR®,
we also help families to preserve newborn stem cells, which are
used today in transplant medicine for certain cancers and blood,
immune and metabolic disorders, and have the potential to play a
valuable role in the ongoing development of regenerative medicine.
For additional company information, please
visit www.amagpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws. Any statements contained herein
which do not describe historical facts, including but not limited
to statements regarding Dr. Simon’s responsibilities at AMAG,
including AMAG’s belief that Dr. Simon’s experience in
pharmacovigilance and risk management will be invaluable to AMAG
are forward-looking statements which involve risks and
uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those
identified in AMAG’s Securities and Exchange Commission (SEC)
filings, including AMAG’s Annual Report on Form 10-K for the year
ended December 31, 2016 and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc. CBR® is a registered trademark
of CBR Systems, Inc.
AMAG Pharmaceuticals, Inc. Contact:
Investors:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
Media:
Rushmie Nofsinger
Executive Director, Corporate Communications & Alliance Engagement
617-498-3332
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Aug 2024 to Sep 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Sep 2023 to Sep 2024